Charles Schwab Investment Management Inc. Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Ultragenyx Pharmaceutical Inc. by 3.3% in the first quarter, owning 593,121 shares valued at approximately $21.5 million.
• Despite the stake reduction, other institutional investors have increased their positions in Ultragenyx, with Federated Hermes Inc. and Point72 Asset Management L.P. both raising their holdings significantly.
• Ultragenyx reported a quarterly revenue of $166.5 million, beating analyst estimates, while its EPS of -$1.17 also surpassed expectations, reflecting a notable growth in revenue of 13.2% compared to the same quarter last year.

Charles Schwab Investment Management Inc. cut its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 593,121 shares of the biopharmaceutical company's stock after selling 20,512 shares during the period. Charles Schwab Investment Management Inc. owned 0.63% of Ultragenyx Pharmaceutical worth $21,477,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $57,000. GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $82,000. Quarry LP bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $84,000. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 231.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,737 shares of the biopharmaceutical company's stock worth $99,000 after purchasing an additional 1,911 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Up 0.1%

RARE stock traded up $0.02 on Tuesday, hitting $29.29. The company had a trading volume of 647,865 shares, compared to its average volume of 1,292,114. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -5.31 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 12-month low of $25.81 and a 12-month high of $60.37. The stock's 50-day simple moving average is $31.54 and its 200 day simple moving average is $35.54.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company's revenue was up 13.2% on a year-over-year basis. During the same period last year, the firm earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on RARE. Canaccord Genuity Group reduced their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Guggenheim reaffirmed a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. William Blair started coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price target on the stock. Wells Fargo & Company reduced their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Finally, Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, July 14th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $81.50.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.50% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.